Immunoblobulin therapy targeting the main immunogenic region of acetylcholine receptor: Animal experiment

2016 Fiscal Year Final Research Report

• Project/Area Number: 26461302
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Neurology
• Research Institution: Nagasaki Institute of Applied Science
• Principal Investigator: MOTOMURA MASAKATSU 長崎総合科学大学, 工学(系)研究科(研究院), 教授 (70244093)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: 重症筋無力症 / アセチルコリン受容体(AChR)抗体 / 主要免疫原性領域(MIR) / 免疫グロブリン療法

Outline of Final Research Achievements

The goal of this study is to develop an immunoglobulin therapy targeting the major immunogenic region (MIR) in the treatment of patients with Acetylcholine Receptor (AChR) antibody positive myasthenia gravis (MG). In this study, we examined its practicality in animal experiments. A protective antibody was prepared by removing the complement binding site of the mAb35 monoclonal antibody, against the common AChR-MIR of humans and rats, and whether or not disease transfer by the antibody can be prevented was examined in an animal experiment in vivo. Unfortunately, in this 　study, it was not possible to prepare mAb35 mutant antibody which does not cause destruction by complement. We will continue to study MIR antibodies that will not cause complement activation.

Free Research Field

神経免疫学